Why the study?
Although doxorubicin is a first-line drug for different types of cancer, drug-induced cardiotoxicity and drug resistance represent major obstacles to therapy.
This review highlights that while doxorubicin is a highly effective anticancer agent, its clinical utility is significantly limited by cardiotoxicity (potentially via free radical generation) and the development of drug resistance.
No takes yet. Share an insight, caveat, or question.
May guide doxorubicin cardiotoxicity mitigation; leaves open validation of resistance strategies in trials.
Al-malky et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: